DENVER (October 8, 2026)—Ashurst Perkins Coie is pleased to have advised Pacira BioSciences, Inc. (Nasdaq: PCRX), a leader in innovative non-opioid pain therapies, on its $1.65 billion acquisition by Viatris Inc. (Nasdaq: VTRS), a global healthcare company. Viatris has acquired Pacira's outstanding common stock shares for $36.50 per share in cash. This significant deal advances Viatris' innovative medicines strategy to become a leader in non-opioid pain therapies.
Serving as main counsel throughout the transaction process, Ashurst Perkins Coie provided legal advice to Pacira, who brings two established, high-margin and patent-protected products and approximately $746 million in total revenue. Viatris plans to extend product lifecycles and sustain meaningful sales to maximize the long-term value of the Pacira portfolio and expects to expand the products' reach across select markets within its global infrastructure.
The Ashurst Perkins Coie team was led by Partner Jason Day, with a core team of Partners Jeff Beuche, Lisa McGimpsey, and Jon Schulman; Counsels Jackie Wilcox and Numaan Deen; and Associates Margaret Heitjan and Dani Buckles.
To learn more, visit: Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
About Ashurst Perkins Coie
